Drug profile · INN
covid-19 vaccine (ad26.cov2-s [recombinant])
JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)
covid-19 vaccine (ad26.cov2-s [recombinant]) (JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)) is a spike glycoprotein vaccine antigen.
EMA: withdrawn Antiinfectives for systemic use (J07) J07BN02
Patents linked 0
Pipeline programs 1
News articles 0
Drug details — covid-19 vaccine (ad26.cov2-s [recombinant])
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 0
- Programs
- 1
- Data quality
- 0.83
Quick answer
covid-19 vaccine (ad26.cov2-s [recombinant]) (JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)) is a spike glycoprotein vaccine antigen.
Key facts
INN covid-19 vaccine (ad26.cov2-s [recombinant])
Brand JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)
Mechanism Spike glycoprotein vaccine antigen
Target Spike glycoprotein
Therapeutic class Antiinfectives for systemic use (J07)
ATC code J07BN02
Mechanism of action
Spike glycoprotein vaccine antigen
Primary target: Spike glycoprotein
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | withdrawn | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is covid-19 vaccine (ad26.cov2-s [recombinant])?
covid-19 vaccine (ad26.cov2-s [recombinant]) (JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN)) is a spike glycoprotein vaccine antigen.
What is the brand name for covid-19 vaccine (ad26.cov2-s [recombinant])?
JCOVDEN (PREVIOUSLY COVID-19 VACCINE JANSSEN) is a marketed brand name for covid-19 vaccine (ad26.cov2-s [recombinant]). Check FDA Drugs@FDA for the current US label holder and prescribing information.